Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2021-03-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于补选公司独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the nomination and election of an independent director candidate. It references compliance with company law, securities law, and stock exchange guidelines, and discusses the nomination process and qualifications of the candidate. There is no financial data, no report or announcement of financial results, no voting results, and no mention of a general meeting or shareholder vote results. The document is related to board/management information, specifically about the nomination and election of a board member. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on management changes, not a report or announcement of a report.
2021-03-11 Chinese
关于对2020年度利润分配事项发表的独立意见
Notice of Dividend Amount Classification · 95% confidence The document is a statement from independent directors expressing their opinion on the 2020 profit distribution proposal, including dividend payment details. It references the annual shareholders meeting and the profit distribution plan but does not contain full financial statements or comprehensive financial data. The document is short (416 characters) and serves as an official opinion on dividend distribution, which aligns with a Notice of Dividend Amount filing rather than a full Annual Report or Earnings Release. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2021-03-11 Chinese
关于获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration approval from the National Medical Products Administration. It details the drug's specifications, regulatory approval, and potential impact on the company. The document is short (1218 characters) and serves as a formal notification to investors and the public about a regulatory milestone, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report but an announcement of a regulatory approval event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-08 Chinese
关于公司左氧氟沙星片拟中选第四批全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the proposed selection of a pharmaceutical product (Levofloxacin tablets) in a national centralized drug procurement program. It includes details about the product, procurement quantity, price, supply regions, and potential impact on the company. The document is short (974 characters) and serves as an announcement of a business event rather than a financial report or detailed management discussion. It does not contain financial statements, audit information, or regulatory certifications. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about a business development that does not fit other specific categories like earnings release, capital update, or management information.
2021-02-03 Chinese
2020年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2020 Annual Performance Forecast' for the company 普洛药业股份有限公司. It provides estimated financial results for the full year 2020, including revenue, net profit, and earnings per share, with comparisons to the previous year. It explicitly states that the data is preliminary, unaudited, and that detailed financial data will be disclosed in the 2020 Annual Report. The document is short (922 characters) and serves as a performance forecast announcement rather than a full financial report. It does not contain actual audited financial statements or comprehensive analysis. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results (key highlights only). FY 2020
2021-01-25 Chinese
关于与上海交通大学签订合作协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the signing of a cooperation agreement with Shanghai Jiao Tong University to establish a joint drug innovation research center. It details the terms of the agreement, funding, duration, and intellectual property arrangements. The document is short (1266 characters) and does not contain financial statements, earnings data, or regulatory certifications. It is an announcement of a corporate cooperation agreement rather than a financial report, management change, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2021-01-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.